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POINT OF VIEW
RESUMEN
El factor de crecimiento semejante a la insulina tipo I (IGF-I) es
una hormona polipeptídica segregada en múltiples tejidos por efec-
to de la hormona de crecimiento (GH). Es responsable de parte de
las acciones de la GH y además tiene efecto hipoglucemiante y ana-
bolizante. El 90% del IGF-I circulante es de origen hepático y ejerce
efectos autocrinos, paracrinos y endocrinos, estos últimos en múlti-
ples tejidos. En la cirrosis hepática se produce una disminución pro-
gresiva de la producción hepática de IGF-I que llega a ser indetecta-
ble en la enfermedad avanzada. Algunas de las complicaciones de la
cirrosis, fundamentalmente nutricionales y metabólicas (resistencia a
insulina, desnutrición, osteopenia, hipogonadismo, alteraciones in-
testinales) podrían estar, al menos en parte, relacionadas con esta
carencia de IGF-I dado que algunas acciones de IGF-I representan la
imagen inversa de las complicaciones de la cirrosis. A pesar de ello,
nunca se había propuesto tratamiento sustitutivo con IGF-I en la ci-
rrosis. En una serie de estudios experimentales realizados en ratas
cirróticas se demostró que el tratamiento con dosis bajas de IGF-I re-
combinante produce dos tipos de efectos en la cirrosis experimen-
tal: a) mejoría del hígado, dado que mejora la función hepatocelular,
la hipertensión portal y la fibrosis hepática; y b) mejoría de las alte-
raciones extrahepáticas de la cirrosis dado que mejora la eficiencia
del alimento ingerido, la masa muscular, la masa ósea, la función y
estructura gonadales y la función y estructura intestinales con nor-
malización de la malabsorción de azúcares y aminoácidos y la mejo-
ría de la función intestinal de barrera manifestada por disminución
de la endotoxemia y la translocación bacteriana. Posteriormente el
primer ensayo clínico piloto, aleatorizado, doble ciego y controlado
con placebo llevado a cabo en un número reducido de pacientes ci-
rróticos demostró aumento de la albúmina sérica y mejoría del me-
tabolismo energético por efecto del IGF-I. Se precisan ensayos clíni-
cos adicionales para identificar la dosis adecuada de IGF-I, el tiempo
y ritmo de administración y el subgrupo de pacientes cirróticos que
obtendrán mayor beneficio de este tratamiento sustitutivo.
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ABSTRACT
Insulin-like growth factor I (IGF-I) is a polypeptide hormone se-
creted by multiple tissues in response to growth hormone (GH). It
is partly responsible for GH activity, and also has glucose-lowering
and anabolizing effects. Ninety percent of circulating IGF-I origi-
nates in the liver and has autocrine, paracrine, and endocrine ef-
fects, the latter on multiple tissues. Liver cirrhosis results in a pro-
gressive decline of hepatic IGF-I output, and this factor may
become undetectable in advanced disease. Some cirrhosis compli-
cations, mainly those nutritional and metabolic in nature (insuline
resistance, malnutrition, osteopenia, hypogonadism, intestinal di-
sorders), may be at least partly related to this IGF-I deficiency, sin-
ce some IGF-I effects represent a reverse image of cirrhosis com-
plications. Despite this, IGF-I replacement therapy has been never
suggested for cirrhosis. A number of experimental studies in cirr-
hotic rats showed that therapy using low-dose recombinant IGF-I
exerts two types of effect on experimental cirrhosis: a) liver impro-
vement driven by improved hepatocellular function, portal hyper-
tension, and liver fibrosis; and b) cirrhosis-related extrahepatic di-
sorder improvement driven by improved food efficiency, muscle
mass, bone mass, gonadal function and structure, and intestinal
function and structure, with a normalization of sugar and amino
acid malabsorption, and improved intstinal barrier function, mani-
fested by reduced endotoxemia and bacterial translocation. Subse-
quently, the first randomized, double-blind, placebo-controlled, pi-
lot clinical trial in a small number of cirrhotic patients showed
increased serum albumin and improved energy metabolism as a
result of IGF-I use. Further clinical trials are needed to identify ade-
quate IGF-I doses, administration duration and frequency, and the
subgroup of cirrhotic patients who will benefit most from this re-
placement therapy.
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INTRODUCTION
Cirrhosis is a chronic, diffuse, irreversible liver dis-
ease characterized by the presence of necrosis, fibrosis,
and regeneration nodules, which change the organ’s
structure and reduce the liver’s functional mass. It is the
final stage of a wide number of chronic liver conditions.
All cirrhosis-related clinical manifestations ultimately
depend on two factors: hepatocellular insufficiency from
progressive hepatocellular mass reduction, and portal hy-
pertension initially due increased intrahepatic resistance
to portal flow, which results from distorted liver architec-
ture. 
For varying periods of time (years) cirrhosis remains
in a “compensated” status, a term applied to patients who
develop no serious complications. Complications arise in
advanced stages, determine a poorer quality of life, and
ultimately lead to the patient’s demise (“decompensated”
cirrhosis).
Most common complications of advanced cirrhosis in-
clude jaundice and coagulopathy from hepatocellular in-
sufficiency, gastrointestinal bleeding from esophageal
varices, ascites, hepatorenal syndrome, spontaneous bac-
terial peritonitis, liver-related encephalopathy, and mal-
nutrition (1,2). Survival in patients with compensated cir-
rhosis is relatively high. At 5 years after diagnosis 90%
of patients remain alive (3), and at 10 years 50%, with a
survival median of 15 years (4). However, should a com-
plication develop, survival significantly decreases to 30%
at 3 years (4). While in the past 20 years drug therapies
have been developed that partly prevent or control some
serious complications, none of them managed to signifi-
cantly increase survival in these patients by modifying
the disorder’s natural history, except for etiologic thera-
pies. Presently, liver transplantation is the only effective
measure to improve the life prognosis of advanced dis-
ease. Therefore, new therapies are needed to modify the
natural history of this disease, and to avoid or delay trans-
plantation, so that the latter may be performed under bet-
ter conditions. These therapies should improve hepato-
cellular function and reduce portal pressure through
anti-inflammatory, anti-fibrogenic, anti-apoptotic, and re-
generative mechanisms.
INSULIN-LIKE GROWTH FACTOR (IGF-I) 
IGF-I is a polypeptide with endocrine, paracrine, and
autocrine effects whose structure is 50% like that of in-
sulin (5). Although many tissues secrete it, more than
90% of circulating IGF-I is synthesized in the liver (6).
Its output is stimulated by growth hormone (GH) (7),
which is secreted by somatotrophic cells in the anterior
pituitary. Liver cells have GH receptors that upon stimu-
lation by the hormone increase IGF-I gene transcription
(8); once synthesized IGF-I is released into plasma. IGF-I
inhibits GH secretion both directly, by acting on the pitu-
itary, and indirectly, by stimulating somatostatin secre-
tion in the hypothalamus, which in turn inhibits GH re-
lease (9). Thus a negative feedback circuit is established.
IGF-I circulates in the blood bound to proteins (IGF-
BP), and interacts with specific receptors in target organs
such as the muscle, bone, intestine, and testicles, among
others (6). 
At least seven binding proteins have been identified
for IGF-I (IGFBPs) (10,11). These play a very important
role in circulating IGF-I bioavailability, and their synthe-
sis is under metabolic and hormonal control. Their func-
tions may be summarized as follows (8): a) they serve as
protein transporters in the plasma and control the flow of
IGF-I from the vascular space to tissues;  b) they prolong
IGF-I half-life and regulate its metabolic clearance; c)
they provide a specific localization tool; and d) they di-
rectly modulate the interaction between IGF-I and its re-
ceptor, and thus indirectly control IGF-I biologic activity. 
In addition, at least some IGFBPs may directly exert
biological effects outside IGF-I signaling pathways
(12,13) including apoptosis induction and cell prolifera-
tion inhibition in some tumors, the latter being the case
for IGFBP3.
Hepatocytes represent the greatest IGFBP1 and IGFBP3
source (9), but Kupffer cells also release IGFBP3 (14). 
IGFBP3, by forming a stable ternary complex with an
acid-labile subunit (ALS) and IGF-I, binds more than
95% of circulating IGF-I5, and its production, as that of
ALS, depends on GH8 and IGF-I (15). The ternary com-
plex increases IGF-I half-life up to 15-20 hours (16), and
thus keeps an IGF-I pool in the vascular compartment.
Following the cleavage of this ternary complex by a pro-
tease IGF-I is released, and may then leave the circula-
tion and enter target tissues with the help of other IGF-
BPs (5). 
IGF-I acts in tissues by binding a specific receptor on
cell membranes. This receptor is very similar to that of
insulin. It is a α2, β2-heterotetramer. Alpha subunits are
extracellular domains with cysteine-rich regions, which
confer specificity to ligands. Beta subunits are cytoplas-
mic domains where tyrosine-kinase activity resides. Ty-
rosine phosphorylation activates a signaling cascade (17).
IGF-I receptors preferentially bind IGF-I, but also IGF-II
and insulin. IGF-I may also interact with other receptors,
including insulin and IGF-II receptors, but with a much
lower affinity (8). Whereas insulin has endocrine effects
predominantly on the liver, fat tissue, and muscle, IGF-I
has paracrine, endocrine, and autocrine effects on nearly
all organs, including the immune system (9). 
Serum IGF-I concentrations depend on GH secretion,
age, gender, and nutritional status (5,18-20).
The relevance of IGF-I for fetal development and dur-
ing childhood and adolescence has been known for years,
as it is the primary factor responsible for many GH ef-
fects. The most significant expression of IGF-I deficien-
cy is Laron-type dwarfism. In this condition an absence
of GH receptors blocks IGF-I production. Early detection
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allows to effectively treat these patients by administering
exogenous rhIGF-I (21,22).
An important role of IGF-I for multiple adult organs
has gained recognition during the past few years. Some
of the reported effects are discussed below. 
Essentially, IGF-I is an anabolic or growth factor. In
protein metabolism it reduces proteolysis and stimulates
protein synthesis when amino acids on offer are adequate
(23). In the muscle it increases muscle mass (24). GH in-
creases amino acid uptake by the muscle through an –at
least partly– non-IGF-I-mediated effect (25), and thus ef-
fects by both substances are synergistic for increased
muscle mass. IGF-I increases glucose use by stimulating
its peripheral uptake, and inhibits liver glucose output
(5). It has therefore an antidiabetic or glucose-lowering
effect similar to insulin. In this respect its action is op-
posed to that of GH, which promotes hyperglycemia.
This IGF-I effect probably aims at countering GH activi-
ty on carbohydrate metabolism, and maintaining eug-
lycemia. In the presence of insulin resistance, besides its
stimulation of glucose use by peripheral tissues, IGF-I re-
duces insulin resistance and insulin secretion by acting
upon beta-cells in the pancreas (5). IGF-I also inhibits
glucagon secretion (26). The effect of IGF-I on fat me-
tabolism is weak. In the bone IGF-I increases the synthe-
sis of collagen by facilitating l-proline transport and in-
corporation (27), and thus contributes to bone mass
maintenance. It has trophic effects on the testicle (28),
and has a trend towards increasing testosterone produc-
tion, which in turn may help increase bone and muscle
mass. In addition, it seemingly has trophic effects on the
bowel, since both the bowel’s length and mass are in-
creased in transgenic mice with IGF-I overexpression, as
are jejunal villi height and crypt depth (29). A trophic ef-
fect on the central nervous system has also been reported,
which results in increases neuronal growth, brain size,
and cortex surface in transgenic mice with IGF-I overex-
pression in the brain (30).
GH-IGF-I SYSTEM CHANGES IN CIRRHOTIC
PATIENTS
Liver cirrhosis is a condition with IGF-I deficiency,
which becomes more severe with disease progression, ac-
cording to all reported studies (31-35). IGF-I levels are
reduced in cirrhotic patients, whereas GH levels are in-
creased (36). IGF-I deficiency results from two factors: a
decrease in GH receptors seen in cirrhotic livers (37-39)
and a progressive reduction of liver synthesis capability
from decreased hepatocellular mass in advanced stages.
Increased GH is accounted for by a lack of negative feed-
back on its secretion when plasma IGF-I declines. The
liver’s unresponsiveness to GH has been revealed by the
infusion of exogenous GH in cirrhotic patients with ad-
vanced disease (Child-Pugh C), which only increases
IGF-I by 10%, while the result is 20% in healthy subjects
with far higher baseline IGF-I levels (34). IGFBPs are
also modified in cirrhosis, with particularly increased
IGFBP1 and decreased IGFBP3 levels, which may alter
this hormone’s bioavailability in tissues (35,40,41).
According to the above, some characteristics of inter-
mediary metabolism and malnutrition in cirrhosis may be
partly justified by IGF-I deficiency. In fact, cirrhotic pa-
tients with malnutrition exhibit characteristics similar to
those of prolonged fasting. Glucose production through
liver gluconeogenesis is increased, as is proteolysis in the
muscle. However, in contrast to healthy fasting subjects,
cirrhotic individuals have increased insulin and glucose
levels, which is typical of insulin resistance. The genesis
of such insulin resistance is not well known. Suggested
causes include high GH, glucagon, and catecholamine
levels, and IGF-I deficiency (42). However, later studies
suggested that neither GH nor glucagon exert a determi-
nant influence over insulin resistance in cirrhotic patients
(40). Schmueli et al. (40) suggest a relevant role for IGF-
BP1 in modulating insulin responsiveness. High IGFBP1
and decreased IGFBP3 levels may restrict IGF-I
bioavailability and, as a consequence, insulin resistance
as seen in cirrhotic subjects may result from reduced
IGF-I bioavailability.
Low IGF-I levels have also been shown to play a role
in the loss of bone mass displayed by cirrhotic individu-
als (43).
Despite the fact that cirrhosis is a specific hormone de-
ficiency (IGF-I) no replacement therapy has ever been
approached with the administration of exogenous IGF-I
in this disease. This fact is in contrast with the clinical
rule of treating hormone deficiencies with exogenous
hormones when available. There is consensus that hy-
pothyroidism, adrenal insufficiency, and diabetes should
be treated with thyroid hormone, glucocorticoids, and in-
sulin, respectively. The hypothesis that IGF-I deficiency
may play a physiological role in the genesis of some cir-
rhosis complications led to suggest experimental studies
to test it. Experimental data supporting the use of IGF-I
as hormone replacement therapy in cirrhosis are dis-
cussed below.
EFFECTS OF rhIGF-I ADMINISTRATION IN
EXPERIMENTAL CIRRHOSIS 
Highly encouraging results in cirrhotic rats treated
with rhIGF-I versus placebo have been reported. Follow-
ing the subcutaneous administration of low-dose rhIGF-I
(20 µg/kg/day) in short courses (14 or 21 days) to rats
with carbon tetrachloride- and phenobarbital-induced cir-
rhosis we observed the following effects:
1. Increased food ingestion, increased efficiency regard-
ing ingested food use, increased uptake of dietary nitrogen
by muscle, and increased nitrogen balance (44), with a re-
sulting increase in muscle mass. All quoted variables were
altered in cirrhotic rats when compared to control rats.
158 M. CONCHILLO ET AL. REV ESP ENFERM DIG (Madrid)
REV ESP ENFERM DIG 2007; 99 (3): 156-164
2. A normalization of galactose intestinal absorption,
and recovery of cirrhosis-associated villi atrophy (45-47).
It should be highlighted that untreated cirrhotic animals
have severe morphologic changes in their intestinal mi-
crovilli, and marked galactose malabsorption. These
findings have been seen both in vivo (46) and in vitro
(45). The fact that functional absorption changes parallel
the structural recovery of intestinal mucosa suggests that
the trophic effect of IGF-I on the mucosa is crucial for
absorption’s return to normal. This effect on jejunal mi-
crovilli has been reported both in early and advanced cir-
rhosis, with a normalization of microvilli atrophy follow-
ing the administration of rhIGF-I (47).
3. A normalization of intestinal absorption for 4 dis-
tinct amino acids in studies of vesicles taken from intesti-
nal mucosal brush borders from both treated and untreat-
ed rats (47,48). As in the above-mentioned galactose
absorption studies, functional changes improve in paral-
lel with morphologic changes. However, moderate lipid
malabsorption as exhibited by cirrhotic animals does not
improve (49).
4. Osteopenia improvement. An increase in bone den-
sity without changes in bone biochemical structure was
reported. This effect results, at least partly, from reduced
bone resorption (50,51).
5. A reversion of testicular atrophy and testicular his-
tological changes occurring in cirrhosis, including loss of
the blood-testicle barrier, decreased tubule diameter,
germ line loss, and reduced cell proliferation and sper-
matogenesis both in early (52) and advanced disease
(53). There is an additional trend towards the normaliza-
tion of pituitary-gonadal axis function (53).
6. A restoration of somatoninergic tone, which is re-
duced in cirrhosis and facilitates the inhibition of GH se-
cretion (54). 
7. Reduced portal pressure, endotoxemia, and bacterial
translocation (55). We highlight the fact that no superpo-
sition of portal pressure values occurred between cirrhot-
ic rats treated and untreated with IGF-I. Improved endo-
toxemia and bacterial translocation likely reflect an
improved intestinal barrier function preventing intralumi-
nal contents leakage. This improvement was seen in asso-
ciation with reduced THF-alpha expression and increased
COX-2 expression in enterocytes by IGF-I. Decreased
portal pressure probably reflects liver histology improve-
ment with reduced fibrosis, but changes in non-structural
aspects cannot be excluded.
8. Improved liver function, regarding both synthesis
(increased albumin and coagulation factor levels) and
transport (reduced bilirubin), and decreased liver fibrosis
(decreased collagen in liver tissue and improved histo-
logical fibrosis score) (56). These findings are striking, as
healthy liver hepatocytes have a low expression of IGF-I
receptors (57), and hence no effect of exogenous IGF-I
on liver tissue could be expected. However, no marked
IGF-I receptor expression has been seen in regenerating
hepatocytes, also in cirrhosis, which could explain this
effects (58). The intimate mechanism for these actions is
unknown in its details. Following therapy with rhIGF-I
cirrhotic rats exhibit a normal mitochondrial function in
the liver (56), a decrease in oxidative stress parameters
and enzymes MPO and iNOS –highly elevated in this
type of carbon tetrachloride-induced cirrhosis– (59)  and
an increase in antioxidating enzymes such as SOD, cata-
lase, and GSHPx (56). From these findings it may be
concluded that IGF-I reduces lipid peroxidation and in-
creases antioxidating activity in the cirrhotic liver, thus
protecting the liver from carbon tetrachloride-induced
damage. In addition, peroxidation products and free radi-
cals can stimulate collagen gene expression in myofi-
broblasts (60), and prolyl-hydroxylase (61) (the enzyme
on which collagen synthesis depends) activity, and acti-
vate stellate cells (62). All these changes regress follow-
ing the administration of low-dose rhIGF-I, which
demonstrates IGF-I’s antifibrogenic effects (63). An in-
teresting study (64) demonstrates that transgenic mice
producing IGF-I under αSMA (α-smooth muscle actin,
expressed in stellate cells in the liver) promoter control
experience a reversion of their carbon tetrachloride-in-
duced tissue damage, and have their transaminase levels
reduced. These effects are seemingly mediated –at least
partly– by the activation of HGF (hepatocyte growth fac-
tor, which stimulates tissue regeneration) and inhibition
of TGFβ1 (stellate cell activator, hepatocyte proliferation
inhibitor, and fibrogenesis promoter).
Several genes have been identified whose expression
is altered in carbon tetrachloride-induced cirrhosis. Treat-
ment with rhIGF-I normalizes expression in half of them
(65). One is serpine 2, a serine-protease inhibitor that is
considered the most relevant protector of mitochondria.
In addition, rhIGF-I increases regenerating activity, thus
increasing proliferating cell nuclear antigen (PCNA) ex-
pression, and partly restores GH receptor gene expres-
sion. It has been also reported to stimulate hepatocyte
growth factor production, this factor being a potent mito-
gen and liver-protecting agent (66). 
Studies performed by another team have demonstrated
the liver-protecting effects of IGF-I in rats with experi-
mental cirrhosis induced by common bile duct ligation.
Animals receiving rhIGF-I had their liver function para-
meters improved, oxidative damage decreased, and fibro-
sis extent reduced in histological studies (67). 
Furthermore, by euglycemic clamping cirrhotic rats
using IGF-I increased glycogen synthesis in muscle tis-
sue and reduced endogenous glucose output were report-
ed, which thus improved insulin resistance (42).
Such liver-protective effects of IGF-I may contribute
to improvements seen in liver function and liver fibrosis.
Overall, then, the administration of low-dose exoge-
nous rhIGF-I to cirrhotic rats improves: 
1. The cirrhotic liver, given improvements seen in liver
fibrosis, hepatocellular function, and portal hypertension.
Increased hepatocellular function and lessened portal hy-
pertension are capital facts from a clinical standpoint, as
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they are determinant of cirrhosis-related clinical manifes-
tations.
2. Cirrhosis-related extrahepatic complications: nutri-
tional status, osteopenia, sugar and amino acid absorp-
tion, intestinal barrier function, and gonadal function and
structure. This improvement probably depends on both
IGF-I’s direct effects on target organs and improved he-
patocellular function.
IGF-I ADMINISTRATION TO NORMAL
SUBJECTS
The actions of IGF-I on metabolism, cardiovascular
function, and renal function were assessed in healthy sub-
jects. Most of these studies involved acute, variable-dose
rhIGF-I administration through the intravenous route in
continual infusion for 2- to 8-hour periods, or through the
subcutaneous route for 4-week periods at most. In both
cases wide dose ranges were used.
Metabolic effects are dependent on, and to a great ex-
tent similar to those of insulin.
The following tables summarize rhIGF-I effects fol-
lowing its administration to healthy subjects:
Table I
Function rhIGF-I effects
Glucose metabolism ↑ glucose uptake
↓ liver glucose output
↑ insulin responsiveness
Hypoglycemia (particularly when IV)
Lipid metabolism ↓ ketones, ↓ triglycerides, ↓ FFA
Protein metabolism ↑ protein synthesis
↓ nitrogen excretion
↑ muscle mass
Improved healing
Renal function ↑ glomerular filtration, ↑ renal plasma flow
Counterregulating hormones ↑ catecholamines
↓ GH, ↓ glucagon
rhIGF-I ADMINISTRATION TO HUMANS
UNDER PATHOLOGIC CONDITIONS
rhIGF-I is a therapeutic agent because of its wide vari-
ety of biological actions on various tissues. As a result of
all such effects it has been posited a therapy against osteo-
porosis (68,69), catabolic situations such as burns (70), di-
abetes (71,72), obesity, neuromuscular disorders (73,74),
GH resistance, and insulin resistance. Overall, it may be
concluded that rhIGF-I has a glucose-lowering effect by
diminishing peripheral insulin resistance, which favors di-
abetes control, increases protein synthesis, induces urinary
nitrogen retention, augments bone and muscle mass, en-
hances muscle strength, and decreases both catabolism and
fat mass. rhIGF-I was used in doses of 15 and 320
µg/kg/day through the subcutaneous route, and tolerability
was excellent for doses below 80 µg/kg/day. Doses of 160
and 320 µg/kg/day were associated with edema, temporo-
mandibular joint complaints, headache, dyspnea, tachycar-
dia, weight gain, gynecomastia, avascular necrosis, Bell’s
paralysis, increased intracranial pressure, and occasional
hypoglycemia episodes. 
When IGF-I levels are very low (Laron-type
dwarfism) therapeutic effects become much more intense
and side effects are nil, which is consistent with the ac-
tions expected from a hormonal replacement therapy,
where a physiologic rather than  pharmacologic effect is
sought.
IGF-I AND CANCER
A theoretical problem regarding IGF-I administration
in cirrhosis is the potential risk of administering a growth
factor is a pre-neoplastic condition such as cirrhosis.
Literature reports suggest a potential role of endoge-
nous IGF-I in tumor growth, but no definite data are
available in this respect (75). Major data are as follows:
1. An epidemiologic study attempted to establish a re-
lationship between serum IGF-I levels and prostate can-
cer (76). Patients whose IGF-I plasma concentrations fell
within the fourth quartile (294-500 ng/ml) had a relative
risk of prostate cancer that was 2.41-fold higher than that
of subjects with IGF-I levels in the first quartile (99-185
ng/ml). Other studies have confirmed this, but no causal
relationship could be established (77).
2. Patients with acromegaly, who are exposed to high
plasma growth hormone, IGF-I, and insulin levels for
years, have an increased risk of colon adenocarcinoma
(78).
3. A positive correlation has been seen between plas-
ma IGF-I levels and breast cancer risk in premenopausal
but not postmenopausal women. No association was
found between IGF-I concentrations and cancer risk
across patients (79). IGF-I is also considered an activity
marker for this type of tumor (80).
4. Epidemiologic studies have suggested that high
IGF-I levels are associated with increased risk for col-
orectal, lung, and prostate cancer when compared to
healthy subjects with lower IGF-I levels (81). 
5. Many tumor cell lines have IGF-I receptors, pro-
duce IGF-I, and respond to IGF-I administration (82).
6. Inhibition of IGF-I-receptor binding using antibod-
ies blocks tumor cell growth in thymusless mice.
Glioblastoma development in rats may be prevented or
treated using immunogenic C6 cells expressing antisense
IGF-I mRNA (83).
7. No data in the literature suggest the malignant trans-
formation of a normal cell in association with IGF-I ad-
ministration.
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8. No tumor development has been reported in patients
receiving IGF-I to this day.
9. IGF- I has not been associated with hepatocarcino-
ma development.
While these studies establish no cause-effect relation-
ship between IGF-I levels and tumor development, it is
only logical that therapies using this hormone have a re-
placement purpose, never elevating IGF-I levels above
upper normal limits in a sustained manner.
rhIGF-1 ADMINISTRATION TO PATIENTS WITH
CIRRHOSIS
Only one clinical trial has been performed thus far
where hIGF-I was chronically administered to cirrhotic
patients (84). It was a pilot, double-blind, randomized,
placebo-controlled study to assess the effects of rhIGF-I
administration to patients with alcohol-related cirrhosis
or primary biliary cirrhosis for four months. Initial doses
of 20 mg/kg/day followed by weekly increases were ad-
ministered to reach a maximum of 50 µg/kg/day or 100
µg/kg/day after four weeks. 
The goal of the study was to administer replacement
therapy by giving in an exogenous manner what patients
could not synthesize. To be included patients had to ex-
hibit very low IGF-I levels (lower than mean IGF-I –2
SDs). 
Eight patients with alcoholic cirrhosis and one with
PBC received rhIGF-1, and seven patients with alcoholic
cirrhosis and two with PBC received placebo. 
The study goals included an assessment of rhIGF-I ef-
fects on the IGF-I/IGFBP system, liver function, and nu-
tritional status. 
When critically assessed this study has two major lim-
itations: a low number of subjects, as this was a pilot
study, and IGF-I doses that failed to fully meet replace-
ment goals, as patients did not achieve normal IGF-I val-
ues over the study period. 
The study showed three main findings in patients re-
ceiving rhIGF-I:
1. A significant increase in serum albumin levels that
correlates to IGF-I/IGFBP3 ratio, an index of IGF-I
bioavailability.
2. A trend towards increased resting energy expendi-
ture (REE) that reaches significance in the alcoholic pa-
tient subgroup.
3. Total IGF-I and IGF-I/IGFBP3 ratio levels rose
among patients receiving rhIGF-1, although IGF-1 con-
centration reached normal values at 7 hours after injec-
tion, only to fall back below normal limits at 24 hours.
IGF-I was more effective in patients with less nutri-
tional impairment, higher hormone bioavailability rates,
and alcoholic cirrhosis. 
Another interesting finding was an excellent tolerabili-
ty with no major side effects ever reported.
FINAL CONSIDERATIONS
Insulin-like growth factor I (IGF-I) may be considered
an early marker of functional reserve or hepatocellular
functional capacity (85,86). A marked decline is seen en
early cirrhosis stages (Child-Pugh A). It is already elevat-
ed before other liver function involvement parameters
(decreased albumin, prolonged prothrombin time, hyper-
bilirubinemia) increase (85). In addition, several studies
have shown that, following the administration of GH to
cirrhotic patients, a greater synthesis of IGF-I screens pa-
tients bound to have better survival (87). A marked de-
cline of IGF-I has also been described to be associated
with a higher probability of hepatocarcinoma (88) and
poorer prognosis in patients requiring liver surgery (89).
As a result IGF-I levels are considered of prognostic val-
ue regarding survival in cirrhotic patients (85,90,91).
IGF-I levels are likely to ultimately result from many
synergistic factors. Primary amongst them is liver disease
severity, with its ensuing loss of hepatocytes and non-
parenchymal liver cells, the ones who can secrete IGF-I
and its binding proteins. Other factors influencing IGF-I
levels include nutritional status (92), portal hypertension
extent, and hyperestrogenism, all of them partly associat-
ed with liver disease development (85).
The association of the liver’s functional stage (Child-
Pugh) with the measurement of IGF-I and IGFBP3 lev-
els, both baseline and following stimulation with GH
(87), predicts disease severity more accurately than
Child-Pugh staging alone (93). 
While liver transplantation is the only effective thera-
py for cirrhosis, it is important that adjuvant treatments
leading to prolonged survival –either from disease and
complication improvement or from making it to trans-
plantation in a condition as good as possible– be investi-
gated. 
The above-mentioned results render further studies nec-
essary to confirm benefits thus far reported. Furthermore,
studies should attempt to establish doses, dosage frequen-
cy, and treatment duration with IGF-I. Whether beneficial
effects are influenced by cirrhosis etiology or disease stage
should be investigated in order to identify patient sub-
groups most likely to benefit from this therapy. These stud-
ies represent a first step towards cirrhosis therapies beyond
complication prevention or treatment, therapies that may
modify the natural history of this disease and hence delay
or ideally cancel liver transplantation.
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